Obesity Treatment Articles & Analysis: Older

1 articles found

Project - Sublingual Dual Incretin Inhibitor (GLP-1/GIP)

BioLingus will position these products in the “epidemic” markets of obesity and type II diabetes : More than 400 MM people suffer from diabetes today. ...

Jan. 30, 2023

ByBioLingus AG

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you